Livzon Pharmaceutical Group Inc. (FRA:LP6)
Germany · Delayed Price · Currency is EUR 3.040
-0.040 (-1.30%)
At close: Jan 30, 2026
FRA:LP6 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 |
Operating Revenue | 11,735 | 11,701 | 12,326 | 12,524 | 11,928 | 10,463 |
Other Revenue | 111.73 | 111.73 | 104.45 | 105.89 | 135.88 | 57.34 |
| 11,847 | 11,812 | 12,430 | 12,630 | 12,064 | 10,520 | |
Revenue Growth (YoY) | -0.09% | -4.97% | -1.58% | 4.69% | 14.67% | 12.10% |
Cost of Revenue | 4,208 | 4,249 | 4,772 | 4,577 | 4,309 | 3,744 |
Gross Profit | 7,639 | 7,564 | 7,658 | 8,053 | 7,754 | 6,777 |
Selling, General & Admin | 3,994 | 3,869 | 4,255 | 4,545 | 4,548 | 3,740 |
Research & Development | 982.13 | 1,033 | 1,335 | 1,427 | 1,146 | 884.1 |
Other Operating Expenses | 126.7 | 120.33 | 133.07 | 143.97 | 135.87 | 122.94 |
Operating Expenses | 5,115 | 5,027 | 5,736 | 6,121 | 5,837 | 4,747 |
Operating Income | 2,524 | 2,536 | 1,921 | 1,932 | 1,917 | 2,029 |
Interest Expense | -64.04 | -88.61 | -102.09 | -97.55 | -84 | -25.31 |
Interest & Investment Income | 384.23 | 265.34 | 429.98 | 359.25 | 251.81 | 323.19 |
Currency Exchange Gain (Loss) | 0.94 | 0.94 | 10.23 | 56.68 | -4.28 | -41.56 |
Other Non Operating Income (Expenses) | 19.01 | -6.98 | -4.42 | -6.37 | -4.01 | -5.89 |
EBT Excluding Unusual Items | 2,864 | 2,707 | 2,255 | 2,244 | 2,077 | 2,280 |
Gain (Loss) on Sale of Investments | -7.49 | -15.44 | -25.65 | -75.27 | -23.03 | 8.81 |
Gain (Loss) on Sale of Assets | 45.26 | 45.2 | -0.17 | 0.86 | 7.03 | -1.07 |
Asset Writedown | 23.32 | -19.86 | -2.43 | -13.99 | -6.15 | -6.9 |
Other Unusual Items | 74.69 | 89.08 | 155.76 | 174.68 | 191.12 | 208.76 |
Pretax Income | 3,000 | 2,806 | 2,383 | 2,331 | 2,246 | 2,489 |
Income Tax Expense | 510.99 | 501.66 | 485.07 | 374.97 | 293.59 | 358.11 |
Earnings From Continuing Operations | 2,489 | 2,304 | 1,898 | 1,956 | 1,952 | 2,131 |
Minority Interest in Earnings | -346.38 | -243.39 | 56.05 | -46.17 | -176.42 | -416.42 |
Net Income | 2,142 | 2,061 | 1,954 | 1,909 | 1,776 | 1,715 |
Net Income to Common | 2,142 | 2,061 | 1,954 | 1,909 | 1,776 | 1,715 |
Net Income Growth | 5.81% | 5.50% | 2.32% | 7.53% | 3.54% | 31.62% |
Shares Outstanding (Basic) | 898 | 920 | 929 | 935 | 935 | 936 |
Shares Outstanding (Diluted) | 898 | 920 | 931 | 936 | 936 | 939 |
Shares Change (YoY) | -2.91% | -1.10% | -0.56% | -0.04% | -0.25% | 0.41% |
EPS (Basic) | 2.38 | 2.24 | 2.10 | 2.04 | 1.90 | 1.83 |
EPS (Diluted) | 2.38 | 2.24 | 2.10 | 2.04 | 1.90 | 1.83 |
EPS Growth | 8.95% | 6.64% | 2.94% | 7.47% | 3.73% | 31.66% |
Free Cash Flow | 2,536 | 2,409 | 2,428 | 1,833 | 593.23 | 1,514 |
Free Cash Flow Per Share | 2.82 | 2.62 | 2.61 | 1.96 | 0.63 | 1.61 |
Dividend Per Share | 1.100 | 1.100 | 1.350 | 1.600 | 1.300 | 1.250 |
Dividend Growth | -18.52% | -18.52% | -15.63% | 23.08% | 4.00% | 8.70% |
Gross Margin | 64.48% | 64.03% | 61.61% | 63.76% | 64.28% | 64.41% |
Operating Margin | 21.30% | 21.47% | 15.46% | 15.30% | 15.89% | 19.29% |
Profit Margin | 18.09% | 17.45% | 15.72% | 15.12% | 14.72% | 16.30% |
Free Cash Flow Margin | 21.41% | 20.39% | 19.54% | 14.51% | 4.92% | 14.39% |
EBITDA | 2,871 | 3,086 | 2,740 | 2,563 | 2,342 | 2,421 |
EBITDA Margin | 24.23% | 26.12% | 22.05% | 20.29% | 19.41% | 23.01% |
D&A For EBITDA | 347.17 | 549.3 | 818.8 | 630.56 | 425.02 | 391.69 |
EBIT | 2,524 | 2,536 | 1,921 | 1,932 | 1,917 | 2,029 |
EBIT Margin | 21.30% | 21.47% | 15.46% | 15.30% | 15.89% | 19.29% |
Effective Tax Rate | 17.03% | 17.88% | 20.36% | 16.09% | 13.07% | 14.38% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.